lopinavir/ritonavir
15 articles related to "lopinavir/ritonavir"
-
A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries
Authors from MSF and Harvard School of Public Health have published a critical analysis of the role of tiered pricing to improve access to medicines in developing countries. The study was presented...
In Medical Journals / Research Articles – Last updated 15 November 2011
www.msfaccess.org/content/win-win-solution-critical-analysis-tiered-pricing-improve-access-medicines-developing -
Brazilians demand greater access to crucial HIV drug
Civil society files patent opposition to increase access to HIV/AIDS medicines Rio de Janeiro, 10 November 2011 – Brazilian civil society will oppose a patent application today for the key...
Press Release – Last updated 11 November 2011
www.msfaccess.org/about-us/media-room/press-releases/brazilians-demand-greater-access-crucial-hiv-drug -
Overcoming patent barriers through compulsory measures
One essential fact is that there are entirely lawful and effective tools to overcome the barriers posed by patents and that hamper access to medicines. There are provisions enshrined in international...
Static page – Last updated 10 April 2012
www.msfaccess.org/content/overcoming-patent-barriers-through-compulsory-measures -
India Rejects Patents for Two Key AIDS Drugs
New Delhi, 7 January 2011 - The Indian Patent Office has just rejected patent applications related to two AIDS medicines – lopinavir/ritonavir and atazanavir - on the basis that they did not merit...
Press Release – Last updated 12 July 2011
www.msfaccess.org/about-us/media-room/press-releases/india-rejects-patents-two-key-aids-drugs -
Heat-stable ritonavir approved
Heat-stable ritonavir approved: Years of medical double standards and stranglehold by Abbott come to an end 12 February 2010 -- Both the European Medicines Agency (EMEA) and the U.S. Food and Drug...
Statements, Speeches, Letters – Last updated 12 February 2010
www.msfaccess.org/content/heat-stable-ritonavir-approved -
Untangling the Web Update to 10th edition
Highlights: · Abbott’s new release of pediatric LPV/r 100/25mg tablet (heatstable) is half the price of the adult tablet. · Gilead offered TDF single and combination...
Report – Last updated 21 February 2008
www.msfaccess.org/content/untangling-web-update-10th-edition -
A bitter pill to swallow
As the morning temperature rises over the sprawling slum of On Nuch, one of Bangkok’s eastern suburbs, 33 year-old Somying and her teenage son are standing on the canal’s bank. For the last...
Web article – Last updated 01 December 2007
www.msfaccess.org/content/bitter-pill-swallow -
Getting Ahead of the Curve
At the 2006 International AIDS Conference (http://www.aids2006.org/), an impressive range of new therapeutic developments for HIV/AIDS were described. Several new drugs, and new drug classes (entry...
In Medical Journals / Research Articles – Last updated 15 January 2007
www.msfaccess.org/content/getting-ahead-curve -
Letter to Abbott. Access to Kaletra in China
Mr. Robert Dintruff Director, Global Care Initiatives Geneva, July 13 2005 Dear Mr. Dintruff, MSF began antiretroviral treatment in 2001 and is now treating more than 34,000 patients in...
Statements, Speeches, Letters – Last updated 11 November 2005
www.msfaccess.org/content/letter-abbott-access-kaletra-china -
Abbott's new and improved Kaletra: Only in the US... But what about the rest of the world?
Médecins Sans Frontières (MSF) is deeply concerned that Abbott’s new version of the secondline fixed dose combination lopinavir/ritonavir – LPV/r, marketed as Kaletra, is not...
Briefing – Last updated 07 February 2006
www.msfaccess.org/content/abbotts-new-and-improved-kaletra-only-us-what-about-rest-world
